Sanxin Medtec(SZ:300453) Xin Lang Cai Jing·2025-10-30 02:26Core Insights - Sanxin Medical (300453.SZ) reported a total operating revenue of 1.168 billion yuan and a net profit attributable to shareholders of 185 million yuan for Q3 2025 [1] - The company achieved a net cash inflow from operating activities of 325 million yuan [1] Financial Performance - The latest debt-to-asset ratio stands at 36.12%, ranking 85th among disclosed peers [3] - The gross profit margin is reported at 35.50%, placing the company 81st among its industry peers [3] - Return on equity (ROE) is at 13.39%, a decrease of 0.06 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.36 yuan [3] - Total asset turnover remained stable year-on-year, with a slight decline of 0.31% compared to the previous year [3] - The inventory turnover ratio is reported at 3.66 times [3] Shareholder Structure - The number of shareholders is 23,100, with the top ten shareholders holding a total of 232 million shares, accounting for 44.43% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: - Peng Yixing: 24.61% - Lei Fenglian: 5.16% - Peng Haibo: 4.75% - Wan Xiaoping: 2.97% - Peng Jiulian: 1.78% - Wu Jianghao: 1.32% - Po Niu: 1.28% - Zhao Yangmin: 0.88% - Xu Guotao: 0.84% - Liang Jinhui: 0.73% [3]